U.S. stocks edge higher after weekly jobless claims; Salesforce gains
LOS ANGELES - Armata Pharmaceuticals, Inc. (NYSE American:ARMP) reported positive results from its Phase 2a diSArm study of AP-SA02 for complicated Staphylococcus aureus bacteremia at IDWeek 2025, according to a company press release. The clinical-stage biotech company, with a market capitalization of $126.48 million, has been focusing on developing its bacteriophage therapy despite reporting an EBITDA of -$33.89 million in the last twelve months, according to InvestingPro data.
The randomized, double-blind trial enrolled 42 patients, with 29 receiving AP-SA02 plus standard antibiotic therapy and 13 receiving placebo with antibiotics alone. The bacteriophage therapy demonstrated significantly higher clinical response rates at day 12 compared to placebo (88% versus 58%, p=0.047) as assessed by site investigators.
Notably, no patients in the AP-SA02 group experienced non-response or relapse at later timepoints, compared to approximately 25% in the placebo group. The therapy appeared effective against both methicillin-resistant (MRSA) and methicillin-sensitive strains of the bacteria.
Dr. Loren G. Miller, Professor of Medicine at UCLA and presenter of the findings, stated, "The results of this rigorously designed study provide strong rationale for advancement into a Phase 3 superiority study."
The bacteriophage cocktail was well-tolerated with no serious adverse events related to the study drug. Treatment-emergent adverse events occurred in only 6% of patients receiving AP-SA02.
The company plans to initiate a pivotal Phase 3 trial in 2026, pending FDA review and feedback. The clinical development of AP-SA02 has been partially supported by a $26.2 million Department of Defense award. The stock has shown remarkable momentum, gaining over 160% in the past six months, trading near its 52-week high of $3.50. InvestingPro subscribers have access to 12 additional investment tips for ARMP, including detailed financial health scores and valuation metrics.
Bacteriophages are viruses that specifically target and kill bacteria while sparing human cells, representing a potential alternative approach to treating antibiotic-resistant infections. With the next earnings report due on November 12, 2025, investors can access comprehensive analysis and Fair Value estimates through InvestingPro to make informed investment decisions in this emerging biotech company.
In other recent news, Armata Pharmaceuticals announced the publication of research in the Journal of Molecular Biology detailing the structure of phage Pa223. This phage is a component of the company's multi-phage clinical candidate AP-PA02. The paper, titled "High-resolution Cryo-EM Analysis of the Therapeutic Pseudomonas Phage Pa223," provides a structural analysis of one of the five phages in AP-PA02. This development is part of Armata's ongoing efforts to advance treatments for chronic respiratory infections. The research focuses on conditions affecting patients with cystic fibrosis and non-cystic fibrosis bronchiectasis. Armata Pharmaceuticals did not release any recent earnings or revenue results. Additionally, there were no announcements regarding mergers or analyst upgrades or downgrades.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.